POOR LONG-TERM OUTCOME OF ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY IN NONPROLIFERATIVE MACULAR TELANGIECTASIA TYPE 2

Retina
Elke H KupitzPeter Charbel Issa

Abstract

To investigate long-term effects after intravitreal inhibition of vascular endothelial growth factor in nonproliferative macular telangiectasia type 2. Nine patients with macular telangiectasia type 2 treated with 12 monthly intravitreal ranibizumab injections in 1 eye were investigated again after a mean follow-up of 6.0 ± 0.4 years. Functional assessment included best-corrected visual acuity and microperimetry testing. Morphologic investigations included optical coherence tomography imaging and fluorescein angiography. Mean visual acuity at baseline was similar in treated and control eyes (both 20/50; range: 20/32-20/125 in the treated eyes and 20/25-20/100 in the untreated eyes). None of the eyes had a neovascular membrane or a paracentral scotoma. At the last follow-up, more eyes of the treatment group had lost 2 or more lines on best-corrected visual acuity testing (4 vs. 1) and more eyes had developed an absolute paracentral scotoma (7 vs. 2). A secondary neovascular membrane had formed in four of the treated and in none of the untreated eyes. Vascular endothelial growth factor inhibition with monthly dosing over 1 year had no beneficial effect 5 years after cessation of therapy. The worse outcome in the treated eyes may ...Continue Reading

References

Apr 4, 2008·Graefe's Archive for Clinical and Experimental Ophthalmology = Albrecht Von Graefes Archiv Für Klinische Und Experimentelle Ophthalmologie·Maria-Andreea GamulescuHorst Helbig
Jun 26, 2008·The British Journal of Ophthalmology·P Charbel IssaH P N Scholl
Oct 22, 2008·Retina·Jaclyn L Kovach, Philip J Rosenfeld
Aug 4, 2010·Ophthalmology·Michael B PownerMarcus Fruttiger
Sep 30, 2010·PloS One·Peter Charbel IssaHendrik P N Scholl
Feb 22, 2011·American Journal of Ophthalmology·Peter Charbel IssaFrank G Holz
Aug 18, 2012·Investigative Ophthalmology & Visual Science·Ferenc B SalloUNKNOWN MacTel Study Group
Oct 25, 2012·Investigative Ophthalmology & Visual Science·Ferenc B SalloUNKNOWN MacTel Study Group
Oct 25, 2012·The Journal of Clinical Investigation·Toshihide KuriharaMartin Friedlander
Nov 9, 2012·The Journal of Neuroscience : the Official Journal of the Society for Neuroscience·Weiyong ShenMark C Gillies
Dec 12, 2012·Progress in Retinal and Eye Research·Peter Charbel IssaHendrik P N Scholl
Apr 26, 2013·Graefe's Archive for Clinical and Experimental Ophthalmology = Albrecht Von Graefes Archiv Für Klinische Und Experimentelle Ophthalmologie·Tobias Meyer-ter-VehnRainer Guthoff
Jun 19, 2013·Ophthalmology·Michael B PownerMarcus Fruttiger
Apr 24, 2014·Ophthalmology·Giovanni StaurenghiUNKNOWN International Nomenclature for Optical Coherence Tomography (IN•OCT) Panel
Jun 13, 2015·Investigative Ophthalmology & Visual Science·Tjebo F C HeerenPeter Charbel Issa

❮ Previous
Next ❯

Citations

Feb 23, 2019·Ophthalmology and Therapy·Alireza KhodabandeBobeck S Modjtahedi
Apr 11, 2019·Acta Ophthalmologica·Daniel PauleikhoffUNKNOWN MacTel Study Group
May 17, 2019·Graefe's Archive for Clinical and Experimental Ophthalmology = Albrecht Von Graefes Archiv Für Klinische Und Experimentelle Ophthalmologie·Daniel PauleikhoffKai Rothaus
Mar 21, 2019·Ophthalmic Surgery, Lasers & Imaging Retina·Panos G ChristakisHenry E Wiley
Jun 10, 2020·The British Journal of Ophthalmology·Simone TzaridisFrank G Holz
Aug 21, 2020·Translational Vision Science & Technology·Katie M LittsCatherine Egan
Aug 15, 2021·Eye·Daniel PauleikhoffEmily Y Chew

❮ Previous
Next ❯

Related Concepts

Related Feeds

Arterial-Venous in Development & Disease

Arterial-venous development may play a crucial role in cardiovascular diseases. Here is the latest research.